Navigation Links
New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits

- Bifantis shows ability to limit inflammation in models of arthritis and Salmonella infection, according to data presented at Digestive Disease Week -

WASHINGTON, May 21, 2007 /PRNewswire/ -- The biotechnology company Alimentary Health today announced results from two studies that demonstrate the anti-inflammatory activity of a natural probiotic bacterial strain of human origin, Bifantis(R) (Bifidobacterium infantis 35624), in models of arthritis and Salmonella infection. Data from these studies were presented this week at the 38th annual Digestive Disease Week (DDW) conference taking place in Washington D.C.

The inflammatory response is a key part of the immune system's battle against invaders, but in certain conditions and diseases, it can do more harm than good by injuring healthy tissue. Inflammation is associated with a variety of conditions, such as inflammatory bowel disease, arthritis, cardiovascular disease, diabetes, Alzheimer's disease and more. Bifantis has previously been shown to modulate the inflammatory response in a clinical trial in irritable bowel syndrome. The results announced this week demonstrate that the anti-inflammatory effects of Bifantis are not restricted to the gastrointestinal tract.

"Inflammation is a major factor in a number of chronic diseases, which affect millions of people," said Barry Kiely, Chief Executive Officer, Alimentary Health and an early investigator of the probiotic effects of Bifantis. "Data continue to show that Bifantis has anti-inflammatory activity, which may be useful in the management of inflammation-linked diseases."

In one of the studies released today, four bacterial strains were fed to mice. Of these four strains, researchers determined that only Bifantis delayed the onset of artificially induced arthritis and resulted in less severe arthritic symptoms. This study represents some of the latest work assessing the link between diet i nvolving probiotics and certain autoimmune diseases.

In the second study, mice were fed Bifantis and then exposed to Salmonella, a common bacteria associated with a form of food poisoning. Animals that received Bifantis showed dramatically increased numbers of certain immune cells that control the immune system's response to harmful pathogens, in this case Salmonella. Bifantis also increased the numbers of T- regulatory cells in the body, in effect limiting the concentrations of certain signals essential to inflammation, such as cytokines.

About Alimentary Health

Alimentary Health is a development stage specialty biotechnology company linked to the Alimentary Pharmabiotic Centre based at University College Cork, Cork, Ireland. Alimentary Health is focused on the discovery, development and commercialization of proprietary treatments for gastrointestinal disorders and other inflammatory conditions.

About APC

The Alimentary Pharmabiotic Centre (APC) is a Science Foundation Ireland (SFI) funded research centre headquartered in University College Cork (UCC), with scientists and clinicians also based in Teagasc Moorepark, Cork University Hospital and Alimentary Health Ltd. The APC is investigating mechanisms by which intestinal bacteria influence health and disease and is developing new therapies for lifelong debilitating gastrointestinal diseases such as gastroenteritis, ulcerative colitis and Crohn's disease. For information please visit http://apc.ucc.ie/.

CONTACT: Barry Kiely, of Alimentary Health, +353-86-8099162,; Adriane Hirsch-Klein, of Manning, Selvage & Lee forAlimentary Health, +1-212-468-4122, BKiely@ahealth.ie Adriane.Hirsch-Klein@mslpr.com

Web site: http://apc.ucc.ie/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
2. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
3. NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology:
(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):